115 related articles for article (PubMed ID: 3121598)
21. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor.
Schleef RR; Higgins DL; Pillemer E; Levitt LJ
J Clin Invest; 1989 May; 83(5):1747-52. PubMed ID: 2496147
[TBL] [Abstract][Full Text] [Related]
22. Kinetic analysis of the interaction between plasminogen activator inhibitor-1 and tissue-type plasminogen activator.
Masson C; Angles-Cano E
Biochem J; 1988 Nov; 256(1):237-44. PubMed ID: 3146972
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 is the primary inhibitor of tissue-type plasminogen activator in pregnancy plasma.
Jørgensen M; Philips M; Thorsen S; Selmer J; Zeuthen J
Thromb Haemost; 1987 Oct; 58(3):872-8. PubMed ID: 3124286
[TBL] [Abstract][Full Text] [Related]
24. Recognition of Plasminogen Activator Inhibitor Type 1 as the Primary Regulator of Fibrinolysis.
Urano T; Suzuki Y; Iwaki T; Sano H; Honkura N; Castellino FJ
Curr Drug Targets; 2019; 20(16):1695-1701. PubMed ID: 31309890
[TBL] [Abstract][Full Text] [Related]
25. The inhibition of tissue type plasminogen activator by plasminogen activator inhibitor-1. The effects of fibrinogen, heparin, vitronectin, and lipoprotein(a).
Edelberg JM; Reilly CF; Pizzo SV
J Biol Chem; 1991 Apr; 266(12):7488-93. PubMed ID: 1708387
[TBL] [Abstract][Full Text] [Related]
26. Purification of an active plasminogen activator inhibitor immunologically related to the endothelial type plasminogen activator inhibitor from the conditioned media of a human melanoma cell line.
Wagner OF; Vetterlein M; Binder BR
J Biol Chem; 1986 Nov; 261(31):14474-81. PubMed ID: 3490474
[TBL] [Abstract][Full Text] [Related]
27. Conversion of the active to latent plasminogen activator inhibitor from human endothelial cells.
Levin EG; Santell L
Blood; 1987 Oct; 70(4):1090-8. PubMed ID: 3498518
[TBL] [Abstract][Full Text] [Related]
28. Mapping of binding sites for heparin, plasminogen activator inhibitor-1, and plasminogen to vitronectin's heparin-binding region reveals a novel vitronectin-dependent feedback mechanism for the control of plasmin formation.
Kost C; Stüber W; Ehrlich HJ; Pannekoek H; Preissner KT
J Biol Chem; 1992 Jun; 267(17):12098-105. PubMed ID: 1376317
[TBL] [Abstract][Full Text] [Related]
29. The active and the inactive plasminogen activator inhibitor from human endothelial cell conditioned medium are immunologically and functionally related to each other.
Sprengers ED; van Hinsbergh VW; Jansen BG
Biochim Biophys Acta; 1986 Sep; 883(2):233-41. PubMed ID: 3091077
[TBL] [Abstract][Full Text] [Related]
30. Some properties of tissue-type plasminogen activator reconstituted onto phospholipid and/or glycolipid vesicles.
Soeda S; Kakiki M; Shimeno H; Nagamatsu A
Biochem Biophys Res Commun; 1987 Jul; 146(1):94-100. PubMed ID: 3111472
[TBL] [Abstract][Full Text] [Related]
31. Immunoaffinity purification of HTC rat hepatoma cell plasminogen activator-inhibitor-1.
Zeheb R; Rafferty UM; Rodriguez MA; Andreasen P; Gelehrter TD
Thromb Haemost; 1987 Dec; 58(4):1017-23. PubMed ID: 3127913
[TBL] [Abstract][Full Text] [Related]
32. Lack of correlation between blood fibrinolysis and the immediate or post-operative blood loss in transurethral resection of the prostate.
Nielsen JD; Gram J; Fabrin K; Holm-Nielsen A; Jespersen J
Br J Urol; 1997 Jul; 80(1):105-10. PubMed ID: 9240188
[TBL] [Abstract][Full Text] [Related]
33. Interactions between tissue-type plasminogen activator and extracellular matrix-associated plasminogen activator inhibitor type 1 in the human hepatoma cell line HepG2.
Owensby DA; Morton PA; Schwartz AL
J Biol Chem; 1989 Oct; 264(30):18180-7. PubMed ID: 2553701
[TBL] [Abstract][Full Text] [Related]
34. The contributions of Ca2+, phospholipids and tissue-factor apoprotein to the activation of human blood-coagulation factor X by activated factor VII.
Bom VJ; Bertina RM
Biochem J; 1990 Jan; 265(2):327-36. PubMed ID: 2302175
[TBL] [Abstract][Full Text] [Related]
35. Both circulating and clot-bound plasminogen activator inhibitor-1 inhibit endogenous fibrinolysis in the rat.
Reilly CF; Fujita T; Mayer EJ; Siegfried ME
Arterioscler Thromb; 1991; 11(5):1276-86. PubMed ID: 1911713
[TBL] [Abstract][Full Text] [Related]
36. Protein S is a cofactor for activated protein C neutralization of an inhibitor of plasminogen activation released from platelets.
D'Angelo A; Lockhart MS; D'Angelo SV; Taylor FB
Blood; 1987 Jan; 69(1):231-7. PubMed ID: 2947643
[TBL] [Abstract][Full Text] [Related]
37. Identification and partial characterization by chemical cross-linking of a binding protein for tissue-type plasminogen activator (t-PA) on rat hepatoma cells. A plasminogen activator inhibitor type 1-independent t-PA receptor.
Bu G; Morton PA; Schwartz AL
J Biol Chem; 1992 Aug; 267(22):15595-602. PubMed ID: 1322401
[TBL] [Abstract][Full Text] [Related]
38. Characterization of a plasminogen activator and its inhibitor in human mesangial cells.
Lacave R; Rondeau E; Ochi S; Delarue F; Schleuning WD; Sraer JD
Kidney Int; 1989 Mar; 35(3):806-11. PubMed ID: 2496257
[TBL] [Abstract][Full Text] [Related]
39. Identification of positively charged residues contributing to the stability of plasminogen activator inhibitor 1.
Gils A; Lu J; Aertgeerts K; Knockaert I; Declerck PJ
FEBS Lett; 1997 Sep; 415(2):192-5. PubMed ID: 9350994
[TBL] [Abstract][Full Text] [Related]
40. Evidence for an active fibrinolytic system in normal human bone marrow.
McWilliam NA; Robbie LA; Barelle CJ; Adey G; Prasad S; Bennett B; Booth NA
Br J Haematol; 1996 Apr; 93(1):170-6. PubMed ID: 8611456
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
